Glaukos Corporation (GKOS) – What Are Investment Firms Saying About This Stock?

Glaukos Corporation (NYSE:GKOS) has received a consensus recommendation of “Moderate Buy” from the fifteen research firms that are currently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and thirteen have issued a buy rating on the company. The average twelve-month price target among brokers that have covered the stock in the last year is $180.54.

A number of analysts recently issued reports on GKOS shares. HC Wainwright upped their target price on Glaukos from $168.00 to $195.00 and gave the company a “buy” rating in a research report on Thursday, July 30th. Weiss Ratings restated a “sell (d-)” rating on shares of Glaukos in a research note on Friday, July 17th. Wall Street Zen raised Glaukos from a “hold” rating to a “buy” rating in a research report on Saturday, August 1st. Jefferies Financial Group boosted their price objective on Glaukos from $190.00 to $210.00 and gave the company a “buy” rating in a research note on Tuesday, September 22nd. Finally, Needham & Company LLC boosted their price objective on Glaukos from $150.00 to $201.00 and gave the company a “buy” rating in a research note on Thursday, July 30th.

Key Glaukos News

Here are the key news stories impacting Glaukos this week:

• Positive Sentiment: iDose TR delivered positive Phase 4 results. Glaukos said its sustained-release glaucoma therapy met the primary endpoint when used with cataract surgery, producing superior eye-pressure reduction versus cataract surgery alone in patients with open-angle glaucoma. The data could support broader adoption of iDose TR and strengthen the company’s commercial glaucoma pipeline. Glaukos Announces Positive Topline Results from Phase 4 Trial
• Positive Sentiment: Three-year Epioxa data showed durable benefits in keratoconus. The Phase 3 extension reported sustained efficacy and a favorable safety profile after a single treatment, supporting the long-term clinical value of Glaukos’ corneal portfolio and potentially improving the therapy’s commercial outlook. Glaukos Announces Positive Three-Year Epioxa Results
• Positive Sentiment: Glaukos expanded its retinal pipeline through an exclusive RevOpsis agreement. The deal covers RO-104, described as a first-in-class tri-specific biologic, along with exclusive rights to the RevMod platform. The agreement adds longer-term retinal growth potential, although the assets remain development-stage programs. Glaukos and RevOpsis Exclusive License Agreement
• Neutral Sentiment: Investor reaction was mixed. Despite the favorable iDose TR and Epioxa updates, market coverage indicated that GKOS shares declined, suggesting investors may be focused on valuation, execution risk, and the financial terms or development costs associated with expanding the retinal pipeline. Glaukos Expands Retina Pipeline
• Negative Sentiment: Insider selling added pressure. Reports said insider sales overshadowed the positive clinical news, potentially raising concerns about management’s confidence or prompting short-term profit-taking after GKOS’s strong longer-term performance. Glaukos Stock Slips on Insider Selling

Insider Buying and Selling at Glaukos

In other news, CFO Alex R. Thurman sold 20,000 shares of Glaukos stock in a transaction on Friday, August 7th. The shares were sold at an average price of $180.13, for a total value of $3,602,600.00. Following the transaction, the chief financial officer directly owned 43,906 shares of the company’s stock, valued at $7,908,787.78. The trade was a 31.30% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Leana Wen sold 525 shares of the company’s stock in a transaction on Friday, July 31st. The shares were sold at an average price of $167.63, for a total transaction of $88,005.75. Following the completion of the sale, the director owned 21,092 shares of the company’s stock, valued at approximately $3,535,651.96. This trade represents a 2.43% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 93,025 shares of company stock valued at $16,550,006. 5.90% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Allworth Financial LP acquired a new position in Glaukos in the second quarter valued at $28,000. CoreCap Advisors LLC purchased a new stake in shares of Glaukos in the third quarter valued at about $33,000. IFP Advisors Inc raised its holdings in shares of Glaukos by 523.4% in the second quarter. IFP Advisors Inc now owns 293 shares of the medical instruments supplier’s stock valued at $41,000 after buying an additional 246 shares during the last quarter. Parallel Advisors LLC boosted its stake in shares of Glaukos by 159.2% during the first quarter. Parallel Advisors LLC now owns 368 shares of the medical instruments supplier’s stock worth $40,000 after buying an additional 226 shares during the period. Finally, Farther Finance Advisors LLC boosted its stake in shares of Glaukos by 25.4% during the third quarter. Farther Finance Advisors LLC now owns 681 shares of the medical instruments supplier’s stock worth $112,000 after buying an additional 138 shares during the period. 99.04% of the stock is owned by hedge funds and other institutional investors.

Glaukos Price Performance

Shares of GKOS opened at $165.37 on Tuesday. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.04 and a quick ratio of 4.46. Glaukos has a 1-year low of $73.16 and a 1-year high of $191.62. The stock has a market cap of $9.75 billion, a PE ratio of -50.88 and a beta of 0.69. The firm has a fifty day moving average price of $172.97 and a 200 day moving average price of $145.88.

Glaukos (NYSE:GKOS) last issued its quarterly earnings data on Wednesday, July 29th. The medical instruments supplier reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.21) by $0.07. Glaukos had a negative return on equity of 6.37% and a negative net margin of 30.68%. The company had revenue of $185.61 million for the quarter, compared to analyst estimates of $150.93 million. During the same quarter last year, the company posted ($0.24) earnings per share. The business’s quarterly revenue was up 49.6% compared to the same quarter last year. As a group, sell-side analysts anticipate that Glaukos will post -0.32 EPS for the current year.

Glaukos Company Profile

Glaukos Corporation is an ophthalmic medical technology company focused on developing and commercializing products intended to preserve and restore vision. The company’s primary business is minimally invasive glaucoma surgery (MIGS), which is designed to reduce intraocular pressure and potentially lessen patients’ dependence on glaucoma medications.

Glaukos’ glaucoma portfolio includes the iStent, iStent inject and iStent infinite systems, which are used in procedures to improve the eye’s natural fluid outflow.